Neurogene Inc. (NGNE) Balance Sheet
As of 2026-06-30 (10-Q), Neurogene Inc. (NGNE) reported total assets of $244.4M, total liabilities of $27.2M and shareholders' equity of $217.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $112.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NGNENeurogene Inc.Follow NGNE — free
—
Price chart with a free account
- Market cap
- 471.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.9 | 39.5 | 32.3 | 52.0 | 76.9 | 143.1 | 192.6 | 142.5 | 82.0 | 148.2 | 136.6 | 103.8 | 112.5 | |
| Short-term investments | 24.2 | 35.0 | 70.8 | 56.1 | — | — | — | 0.0 | 0.0 | 48.9 | 175.8 | 165.2 | 112.9 | |
| Receivables | 0.1 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | |
| Current assets | 39.3 | 74.8 | 103.5 | 108.8 | 77.2 | 143.6 | 194.5 | 144.0 | 84.7 | 200.3 | 315.9 | 271.8 | 228.9 | |
| Total assets | 41.4 | 113.3 | 154.4 | 110.3 | 77.6 | 147.0 | 210.5 | 163.3 | 109.3 | 222.6 | 335.7 | 288.6 | 244.4 | |
| Current liabilities | 5.2 | 4.8 | 9.5 | 11.0 | 4.6 | 4.7 | 7.9 | 8.6 | 6.7 | 23.0 | 15.2 | 16.4 | 21.5 | |
| Total liabilities | 5.3 | 4.9 | 9.7 | 11.4 | 4.9 | 5.3 | 19.3 | 20.4 | 10.6 | 36.5 | 25.4 | 23.7 | 27.2 | |
| Shareholders' equity | 36.1 | 108.4 | 144.7 | 98.9 | 72.7 | 141.7 | 191.2 | -91.9 | -145.7 | 186.0 | 310.4 | 264.9 | 217.1 |
USD millions · SEC XBRL
Neurogene Inc. — questions
- How much cash does Neurogene Inc. have?
- $112.5M in cash and cash equivalents as of 2026-06-30.
- What are Neurogene Inc.'s total assets?
- $244.4M as of 2026-06-30.
- What is Neurogene Inc.'s shareholders' equity?
- $217.1M as of 2026-06-30.
Every figure on this page comes from Neurogene Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.